Napredna pretraga

Pregled bibliografske jedinice broj: 782037

Proton pump inhibitors, hypomagnesemia and cardiovascular risk in hemodialysis patients


Jakopčić, Ivan; Orlić, Lidija; Carović, Franjo; Rački, Valentino; Prskalo, Mila; Lukenda Žanko, Vesna; Rački, Sanjin; Pavlović, Draško; Gulin, Marijana; Klarić, Dragan et al.
Proton pump inhibitors, hypomagnesemia and cardiovascular risk in hemodialysis patients // BANTAO Journal
Opatija, Hrvatska, 2015. str. 82-82 (predavanje, međunarodna recenzija, sažetak, ostalo)


Naslov
Proton pump inhibitors, hypomagnesemia and cardiovascular risk in hemodialysis patients

Autori
Jakopčić, Ivan ; Orlić, Lidija ; Carović, Franjo ; Rački, Valentino ; Prskalo, Mila ; Lukenda Žanko, Vesna ; Rački, Sanjin ; Pavlović, Draško ; Gulin, Marijana ; Klarić, Dragan ; Ladavac, Ranko ; Gulin, Marko ; Mikolašević, Ivana

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo

Izvornik
BANTAO Journal / - , 2015, 82-82

Skup
12th Congress of the Balkan Cities Association of Nephrology, Dialysis, Transplantation and Artificial Organs 6th Croatian Symposium on Renal Replacment Therapy

Mjesto i datum
Opatija, Hrvatska, 15-18.10.2015

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Proton pump inhibitors ; hypomagnesemia
(Pproton pump inhibitors ; hypomagnesemia)

Sažetak
BACKGROUND: Recent observations have associated low magnesium (Mg) levels with increased risk of cardiovascular (CVD) morbidity and mortality in hemodialysis (HD) patients. There have been some small studies of hypomagnesemia due to use of proton-pump inhibitors (PPIs). Since patients with end-stage renal disease have little to no kidney Mg loss to affect serum Mg concentration, HD patients are an interesting population in whom to study the relationship between PPI use and serum Mg levels. METHODS: A total of HD 418 patients were screened for inclusion, with 159 excluded due to either incomplete medical data, use of Mg-based phosphate binders or other Mg-based medications or presence of chronic increased GI losses. Among 259 patients included in the study, 160 patients were on PPIs, and median time on the PPIs was 25.2±20 months. There was no significant difference in dialysate Mg concentrations between the PPIs-users and non- users (0.6±0.1vs.0.6±0.1 ; p=0.750). RESULTS: The most common prescribed PPIs was pantoprazole (67.5%). There were no significant differences between the two groups in age, presence of diabetes, duration of HD, or mean values for calcium, phosphorus, albumin or iPTH. Pre-and postdialysis systolic and diastolic blood pressures were also not different between the two groups, as well as diuretic use (29.4%vs.34.3 ; p=0.483). Serum Mg levels were significantly lower among PPI users vs. non-users (0.96vs.1.02 mmol/L, p=0.028). The daily PPIs dose almost reached the significant correlation with low Mg levels (r=0.138 ; p=0.080). The duration of PPIs use (r=0.128 ; p=0.142) wasn´t significantly associated with Mg levels. Although, PPI users had higher rate of adverse CVD events during the one year of follow-up in comparison to non- users, that difference wasn’t statistically significant (17.5%vs.11.1% ; p=0.110). CONCLUSION: Among HD patients, PPI users have lower serum Mg levels as compared with non- users. This observational investigation indicate the need for interventional studies to confirm a cause-effect relationship between hypomagnesemia, PPI use and adverse CVD outcomes in HD patients.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Časopis indeksira:


  • Scopus